Matthew Bin Han Ong, associate editor of The Cancer Letter, was named by the Poynter Institute and The Washington Post to the Leadership Academy for Diversity in Digital Media.
Gary Reedy announced that he will retire from his job as CEO of the American Cancer Society when his contract expires next April.
At The Cancer Letter, we watched with growing alarm as early warnings of the virulence of SARS-CoV-2 started pouring in from Wuhan, and later, from Lombardy.
For cancer epidemiologists, the COVID-19 pandemic is a natural experiment in the importance of screening, early detection, and diagnosis.
Like a laser, COVID-19 traced the shocking contours of inequality in America's health system—demonstrating that science and health equity have always been inseparable.
As a Latina, I feel deeply impacted when I see reports of hate crimes against ethnic and racial minorities in the news. The recent string of news reports highlighting police brutality and the victimization of black people has caused a great deal of pain in my heart, prompting me to reflect on my own experiences.
A reading list is a glimpse into the soul of a community. A reading list is also a reflection of a time. And a projection of visions of the future.
In 1971, when the National Cancer Act was signed, Walter Lawrence, Jr., was one of the surgeons eager for a push forward, driven by rigorous science reviewed and funded by the federal government.
Tecentriq (atezolizumab) received FDA approval in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Tecartus (brexucabtagene autoleucel), a cell-based gene therapy, received FDA approval for treatment of adult patients diagnosed with mantle cell lymphoma who have not responded to or who have relapsed following other kinds of treatment.
